14:32:30 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-15 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-23 Ordinarie utdelning IMP A 0.00 SEK
2024-05-22 Årsstämma 2024
2024-05-15 Kvartalsrapport 2024-Q1
2024-02-16 Bokslutskommuniké 2023
2023-11-22 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-26 Ordinarie utdelning IMP A 0.00 SEK
2023-05-25 Årsstämma 2023
2023-05-12 Kvartalsrapport 2023-Q1
2023-02-17 Bokslutskommuniké 2022
2022-11-15 Kvartalsrapport 2022-Q3
2022-08-23 Kvartalsrapport 2022-Q2
2022-05-11 Ordinarie utdelning IMP A 0.00 SEK
2022-05-11 Kvartalsrapport 2022-Q1
2022-05-10 Årsstämma 2022
2022-02-18 Bokslutskommuniké 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-09-17 Extra Bolagsstämma 2021
2021-08-24 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-04-19 Ordinarie utdelning IMP A 0.00 SEK
2021-04-16 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-18 Kvartalsrapport 2020-Q3

Beskrivning

LandLiechtenstein
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Implantica är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar implanterbara medicinska instrument, som vidare används för behandling av sjukdomar som berör matstrupen. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster, särskilt inriktat mot eHälsa. Verksamheten drivs globalt med störst närvaro inom Nordamerika samt Europa.
2023-11-17 08:00:00

Implantica AG (publ) invites investors to a presentation of the third quarter 2023 at 15:00 CET on November 22. The interim report for the third quarter will be published at 8:00 a.m. CET on the same day.

The presentation will be in English via an audiocast with teleconference:

If you wish to participate via webcast, please use the following link:If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference.Speakers:
  • CEO Peter Forsell
  • CFO Andreas Öhrnberg
  • Chief Corporate Affairs Officer Nicole Pehrsson

For further information, please contact:

Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, info@fnca.se

The information was sent for publication, through the agency of the contact person set out above, on November 17, 2023 at 08:00 a.m. CET.

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.